Jade Biosciences Gets Two Catalysts, but Focus Is on 2027
Jade Biosciences is set to open Thursday in the U.S. after announcing it started dosing patients in two clinical trials. The company said it began a Phase 2 study in kidney disease and a first-in-human study in rheumatoid arthritis. Shares last changed hands at $21.50, off 21 cents from the previous close, in premarket activity. That’s important as Jade shifts from early promise to actual patient data. A Phase 2 study gives an early look at whether a drug helps patients, while Phase 1 is just the initial test in people, mainly covering safety, drug exposure, and first biological effects.